Company news
Vyne Therapeutics Inc. (NASDAQ:VYNE) news
Vyne Therapeutics Inc. news releases on 6ix. Latest, Aug 12, 2022: VYNE Therapeutics Reports Second Quarter 2022 Financial Results
Press releases — page 2
VYNE Therapeutics Reports Second Quarter 2022 Financial Results
August 11, 2022
VYNE Therapeutics Announces Results from its Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
August 9, 2022
VYNE Therapeutics Completes Enrollment in Phase 2a Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
June 16, 2022
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
VYNE Hosting Key Opinion Leader Event on Novel InhiBET™ BET Inhibitor Platform
May 9, 2022
VYNE Therapeutics Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
April 6, 2022
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
March 29, 2022
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
March 16, 2022
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
March 6, 2022
VYNE Therapeutics Announces Phase 1b Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis
January 18, 2022
VYNE Therapeutics Divests Topical Minocycline Assets
January 12, 2022
VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
November 9, 2021
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
October 27, 2021
VYNE Therapeutics Announces Formation of Scientific Advisory Board
October 20, 2021
VYNE Therapeutics Enrolls First Patient in Clinical Trial of FMX114 for the Treatment of Mild-to-Moderate Atopic Dermatitis
October 18, 2021
VYNE Therapeutics Announces its China Partner’s Enrollment of First Patient in Phase 3 Study of AMZEEQ® in Patients with Moderate to Severe Acne
October 4, 2021
VYNE Therapeutics Reports Second Quarter 2021 Financial Results and Announces New Strategic Direction to Develop Treatments for Immunological and Inflammatory Diseases
August 11, 2021
VYNE Therapeutics Announces Licensing of BET Inhibitor Platform for Immuno-Inflammatory Conditions with In4Derm Limited
August 11, 2021
VYNE Therapeutics Announces Approval of AMZEEQ® (Minocycline) and ZILXI® (Minocycline) in Chinese Economic Pilot Zone
August 1, 2021
VYNE Therapeutics to Report Second Quarter 2021 Financial Results on August 12, 2021
July 26, 2021
VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ® (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne
July 18, 2021
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 5, 2021
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
April 27, 2021
VYNE Therapeutics Reports Year-End 2020 Financial Results and Provides Business Update
March 3, 2021
VYNE Therapeutics Announces Development Program for FMX114 Combination Topical Gel for Mild-to-Moderate Atopic Dermatitis
February 28, 2021
VYNE Therapeutics Announces FDA Approval of AMZEEQ® (Minocycline) Label Update
January 31, 2021
VYNE Therapeutics Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update
January 28, 2021
VYNE Therapeutics Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
January 25, 2021
VYNE Therapeutics Announces Contract Execution for AMZEEQ® (minocycline) and ZILXI® (minocycline) with Major Pharmacy Benefit Management (PBM) Company
January 20, 2021
VYNE Therapeutics Reports Successful End-of-Phase 2 Meeting with the FDA for FCD105 in Acne
December 16, 2020
VYNE Therapeutics Announces New U.S. Patent Expiring in 2037 for AMZEEQ® (minocycline) topical foam, 4%
December 14, 2020
VYNE Therapeutics Announces Publication of Long-term Safety & Efficacy Data for ZILXI™ (minocycline) topical foam, 1.5% in the Journal of Clinical and Aesthetic Dermatology
November 30, 2020
VYNE Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
VYNE Therapeutics to Report Third Quarter 2020 Financial Results on November 5th
October 27, 2020
VYNE Therapeutics Announces Covered Status for ZILXI™ (minocycline) with Express Scripts
October 6, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% is Available in Pharmacies Nationwide Today, October 1st
September 30, 2020
VYNE Therapeutics Announces ZILXI™ (minocycline) topical foam, 1.5% Available in Pharmacies Nationwide on October 1st
September 30, 2020
VYNE Therapeutics to Host Physician Symposium on AMZEEQ® and ZILXI™
September 22, 2020
VYNE Therapeutics Announces the Appointment of Patrick G. LePore to its Board of Directors
September 13, 2020